Early PSA response to antiandrogen therapy in metastatic castration-resistant prostate carcinoma patients: A predictive marker for progression-free survival?

---

Atıf İçin Kopyala

Atakan D., Ozkan A., Guven M. A. , Sinan K.

JOURNAL OF BUON, cilt.25, sa.3, ss.1625-1630, 2020 (SCI İndekslerine Giren Dergi)

• Cilt numarası: 25 Konu: 3
• Basım Tarihi: 2020
• Dergi Adı: JOURNAL OF BUON
• Sayfa Sayıları: ss.1625-1630

Özet

Purpose: Enzalutamide and abiraterone acetate (AA) are the main therapeutic approaches for the treatment of metastatic castration-resistant prostate cancer (mCRPC) after the failure of androgen deprivation therapy during or following docetaxel-based chemotherapy. The aim of the present study was to investigate the role of early prostate-specific antigen (PSA) decline (four weeks after anti-androgen therapy) in predicting long-term progression free survival (PFS).